Vaccine Info

Russian COVID-19 Vaccine

Russian COVID-19 Vaccine Description

The Russian COVID-19 vaccine candidate uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

Russian COVID-19 vaccine candidate is a vector vaccine SICEM based on adenovirus DNA, in which the SARS-CoV-2 coronavirus gene is integrated. 

Adenovirus is used as a “container” to deliver the coronavirus gene to cells, start the synthesis of the envelope proteins of the new coronavirus “introducing” the immune system to a potential enemy.

The vaccine is alleged to reduce the time taken for the actual development of immunity to SARS-CoV-2, the virus behind the COVID-19 pandemic

The first vaccination leads to humoral cellular immunity and once a second vaccine is administered, a key feature of this vaccine kicks in—memory cells are formed.

In May 2020, a state institute, the Gamaleya National Research Centre of Epidemiology and Microbiology, announced that it had developed the vaccine, which does not have any side effects. 

The Russian COVID-19 vaccine candidate was developed by the same government labs that developed what is claimed “an effective against the Ebola virus, as well as a vaccine against the MERS virus (Middle East respiratory syndrome).”

Russian COVID-19 Vaccine Indication

Russian COVID-19 Vaccine candidate is indicated to build immunity to SARS-CoV-2 the virus which causes COVID-19 disease.

Russian COVID-19 Vaccine News

June 11, 2020 - Hit Hard by Coronavirus, Russia Joins Global Race for a Vaccine.

June 10, 2020 - RDIF has supported the development of a Russian COVID-19 vaccine that is scheduled to commence clinical trials by mid-June 2020 and enter production by the fall.

June 4, 2020 - Russia plans to start clinical testing of a coronavirus vaccine on paid volunteers from the general public

May 22, 2020 - Russian developers of a coronavirus vaccine have developed immunity to the infection after self-administering it.

Russian COVID-19 Vaccine Clinical Trials

Russian COVID-19 vaccine is scheduled to commence clinical trials by mid-June 2020 and enter production by the fall.

  • Two groups of volunteers were selected out of a pool of military personnel and civilians. 
  • The Russian Defense Ministry told the Russian press that 50 “servicemen,” including 10 medical workers, would be placed on a 14-day quarantine on June 4 and 9.
  • The military personnel participants are between the ages of 25 to 50 years.
  • As part of their protocol, the participants must go through quarantine to exclude the potential of transmitting the infection to other participants and medical personnel.

No study has been published about the vaccine, and there has been no independent confirmation of the statements made by scientists or government members. 

06/14/2020 - 12:54